본문 바로가기
KERD
논문KCI 등재

Clinical Implications of the Serum Apelin Level on Portal Hypertension and Prognosis of Liver Cirrhosis

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

초록

Background/Aims: Levels of serum apelin (s-apelin), an endogenous ligand for angiotensin-like receptor 1, have been shown to be related to hepatic fibrosis and hemodynamic abnormalities in preclinical studies. We investigated the clinical implications of s-apelin as a noninvasive prognostic biomarker for chronic liver disease (CLD). Methods: From January 2009 to December 2012, 215 CLD patients were enrolled and underwent clinical data collection, hepatic venous pressure gradient (HVPG) measurement, and liver biopsy. s-apelin was detected with a human total apelin enzyme-linked immunosorbent assay kit. All patients were prospectively observed during the median follow-up period of 23.0±12.9 months for decompensation and mortality. Results: A total of 42 patients (19.5%) died during the follow-up period. s-apelin was significantly correlated with measurements of liver stiffness (R2=0.263, p<0.001) and collagen proportional area (R2=0.213, p<0.001) measured from liver biopsy tissue and HVPG (R2=0.356, p<0.001). In a multivariate analysis using a Cox regression hazard model, s-apelin was a weakly significant predictor of decompensation (hazard ratio [HR], 1.002; p<0.001) and mortality (HR, 1.003; p<0.001). Conclusions: s-apelin showed a significant relationship with CLD severity. However, its significance as a noninvasive biomarker for disease severity and prognosis was weak.

Abstract

Background/Aims: Levels of serum apelin (s-apelin), an endogenous ligand for angiotensin-like receptor 1, have been shown to be related to hepatic fibrosis and hemodynamic abnormalities in preclinical studies. We investigated the clinical implications of s-apelin as a noninvasive prognostic biomarker for chronic liver disease (CLD). Methods: From January 2009 to December 2012, 215 CLD patients were enrolled and underwent clinical data collection, hepatic venous pressure gradient (HVPG) measurement, and liver biopsy. s-apelin was detected with a human total apelin enzyme-linked immunosorbent assay kit. All patients were prospectively observed during the median follow-up period of 23.0±12.9 months for decompensation and mortality. Results: A total of 42 patients (19.5%) died during the follow-up period. s-apelin was significantly correlated with measurements of liver stiffness (R2=0.263, p<0.001) and collagen proportional area (R2=0.213, p<0.001) measured from liver biopsy tissue and HVPG (R2=0.356, p<0.001). In a multivariate analysis using a Cox regression hazard model, s-apelin was a weakly significant predictor of decompensation (hazard ratio [HR], 1.002; p<0.001) and mortality (HR, 1.003; p<0.001). Conclusions: s-apelin showed a significant relationship with CLD severity. However, its significance as a noninvasive biomarker for disease severity and prognosis was weak.

참고문헌 (21)

  1. Arvaniti V, "Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis", Gastroenterology, 139, pp.1246~1256 (2010)
  2. Garcia-Tsao G, "Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis", Hepatology, 51, pp.1445~1449 (2010)
  3. Kim MY, "Hemodynamic alterations in cirrhosis and portal hypertension", Korean J Hepatol, 16, pp.347~352 (2010)
  4. 박의주, "The Risk Factors for Bleeding of Fundal Varices in Patients with Liver Cirrhosis", Gut and Liver, 7(6), pp.704~711 (2013), 거트앤리버 발행위원회
  5. 이태훈, "Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score", Gut and Liver, 7(3), pp.323~328 (2013), 거트앤리버 발행위원회
  6. Garcia-Tsao G, "Outpatient liver biopsy: how safe is it?", Ann Intern Med, 118, pp.150~153 (1993)
  7. Lebrec D, "Methods to evaluate portal hypertension", Gastroenterol Clin North Am, 21, pp.41~59 (1992)
  8. Kim MY, "Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis", Hepatology, 56, pp.1053~1062 (2012)
  9. O’Dowd BF, "A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11", Gene, 136, pp.355~360 (1993)
  10. Tatemoto K, "Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor", Biochem Biophys Res Commun, 251, pp.471~476 (1998)
  11. Ishida J, "Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo", J Biol Chem, 279, pp.26274~26279 (2004)
  12. Tatemoto K, "The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism", Regul Pept, 99, pp.87~92 (2001)
  13. De Mota N, "Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release", Proc Natl Acad Sci U S A, 101, pp.10464~10469 (2004)
  14. Principe A, "The hepatic apelin system: a new therapeutic target for liver disease", Hepatology, 48, pp.1193~1201 (2008)
  15. Tiani C, "Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension", J Hepatol, 50, pp.296~305 (2009)
  16. Melgar-Lesmes P, "Hypoxia and proinflammatory factors upregulate apelin receptor expression in human stellate cells and hepatocytes", Gut, 60, pp.1404~1411 (2011)
  17. Kim MY, "Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis", Eur J Gastroenterol Hepatol, 21, pp.1241~1246 (2009)
  18. de Franchis R, "Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension", J Hepatol, 33, pp.846~852 (2000)
  19. 홍원기, "The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data", Clinical and Molecular Hepatology, 19(4), pp.370~375 (2013), 대한간학회
  20. Kim MY, "Invasive and non-invasive diagnosis of cirrhosis and portal hypertension", World J Gastroenterol, 20, pp.4300~4315 (2014)
  21. Tsochatzis E, "Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis", J Hepatol, 60, pp.948~954 (2014)

관련 논문AI추천

Combined effect of hepatic venous pressure gradient and liver stiffness on long-term mortality in patients with cirrhosis이재곤, Jae Yoon Jeong, Joo Hyun Sohn, Sun Min Kim, Tae Yeob Kim, Yongsoo Kim, Young Seo Cho대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제1호Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension엄영우, Kwang Yong Shim, Moon Young Kim, Seong Hee Kang, Soon Koo Baik대한내과학회 · The Korean Journal of Internal Medicine2018 · 제33권 제3호Recent Advances in the Pathogenesis and Clinical Evaluation of Portal Hypertension in Chronic Liver DiseaseKawada Norifumi, Kotani Kohei거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제1호The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data강용석, 강혜원, 권상옥, 김문영, 김영주, 김정민, 김현아, 백순구, 신승용, 이진형, 임유리, 조연주, 채명훈, 홍원기, 황혜원대한간학회 · Clinical and Molecular Hepatology2013 · 제19권 제4호The cut-off value of transient elastography to the value of hepatic venous pressure gradient in alcoholic cirrhosisBaigal Baymbajav, Jae Young Jang, Jeong-Ju Yoo, Moon Young Kim, Sang Gyune Kim, Seong Hee Kang, Se Ri Ryu, Soon Koo Baik, Soung Won Jeong, Su Yeon Park, Yong Jae Kim, Young Chang, Young Kyu Cho, Young Seok Kim대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제1호Relationship between the hepatic venous pressure gradient and first variceal hemorrhage in patients with cirrhosis: a multicenter retrospective study in Korea김동준, 김문영, 김상균, 김영석, 김홍수, 백순구, 석기태, 이세환, 장재영, 정승원, Boo Sung Kim, Ho Eun Jung, Jin Nyoung Kim, Kyoung Min Sohn대한간학회 · Clinical and Molecular Hepatology2012 · 제18권 제4호

이 간행물의 다른 논문 (23건)